Information Journal Paper
APA:
Copy. (2017). Cytotoxicity of selenium trastuzumab and bevacizumab immunoconjugates against triple negative breast cancer cells. CANCER RESEARCH, 77(13 .Suppl), 4613-4613. SID. https://sid.ir/paper/746479/en
Vancouver:
Copy. Cytotoxicity of selenium trastuzumab and bevacizumab immunoconjugates against triple negative breast cancer cells. CANCER RESEARCH[Internet]. 2017;77(13 .Suppl):4613-4613. Available from: https://sid.ir/paper/746479/en
IEEE:
Copy, “Cytotoxicity of selenium trastuzumab and bevacizumab immunoconjugates against triple negative breast cancer cells,” CANCER RESEARCH, vol. 77, no. 13 .Suppl, pp. 4613–4613, 2017, [Online]. Available: https://sid.ir/paper/746479/en